Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pandemic flu H5 mRNA vaccine · 1 trial · 1 indication
Number of participants experiencing immediate AEs
Number of participants experiencing solicited injection site reactions
Number of participants experiencing solicited systemic site reactions
Number of participants experiencing unsolicited AEs
Number of participants experiencing MAAEs
Number of participants experiencing AESIs
Number of participants experiencing SAEs
Number of participants with out-of-range biological test results
| Arm | Type | Description |
|---|---|---|
| Group 1: Low Dose Pandemic flu H5 mRNA vaccine | EXPERIMENTAL | Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22) |
| Group 2: Medium Dose Pandemic flu H5 mRNA vaccine | EXPERIMENTAL | Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22) |
| Group 3: High Dose Pandemic flu H5 mRNA vaccine | EXPERIMENTAL | Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22) |
| Group 4: Placebo | PLACEBO_COMPARATOR | Participants will receive 2 injections of placebo 21 days apart (at Day 01 and Day 22) |
| Name | Type | Description |
|---|---|---|
| Pandemic flu H5 mRNA vaccine | BIOLOGICAL | Pharmaceutical Form: Suspension for injection Route of Administration: Intramuscular (IM) |
| Placebo | OTHER | Pharmaceutical Form: Liquid solution for injection Route of Administration: Intramuscular (IM) |
Inclusion Criteria: * Aged 18 years or older on the day of inclusion. * A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * Is of non-childbearing potential. To be considered of non-childbearing potential, a femal...
Pandemic flu H5 mRNA vaccine is an investigational vaccine for influenza immunization. It is designed to protect against pandemic flu caused by the H5 influenza strain. The vaccine is currently in Phase 1 clinical development and is not yet approved for use.
Pandemic flu H5 mRNA vaccine is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker SNY. The vaccine is currently in Phase 1 clinical trials for influenza immunization.
Pandemic flu H5 mRNA vaccine is in Phase 1 clinical development. It is an investigational vaccine for influenza immunization and has not been approved by regulatory authorities. A Phase 1 trial has been completed to evaluate its safety and immunogenicity.
Pandemic flu H5 mRNA vaccine has one completed Phase 1 trial, NCT06727058, which evaluated its safety and immunogenicity in healthy adults aged 18 years and older in the United States. The trial enrolled 276 participants and was randomized, double-blind, and placebo-controlled.
Pandemic flu H5 mRNA vaccine is an investigational mRNA vaccine specifically designed for pandemic flu caused by the H5 strain. It is not the same as a seasonal flu shot, which targets different strains. The vaccine is still in clinical development and not yet available to the public.